AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s stock price rose 10.7% during mid-day trading on Wednesday . The company traded as high as $10.27 and last traded at $10.02. Approximately 79,259 shares were traded during mid-day trading, an increase of 405% from the average daily volume of 15,685 shares. The stock had previously closed at $9.05.
AlloVir Stock Performance
The stock’s 50-day simple moving average is $8.83 and its two-hundred day simple moving average is $6.03. The stock has a market cap of $50.53 million, a price-to-earnings ratio of -0.50 and a beta of 0.63.
AlloVir Company Profile
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Recommended Stories
- Five stocks we like better than AlloVir
- Is THIS the Next Big Money Rush?
- Wall Street Legend Names #1 Stock of 2026 Live On-Camera
- ISPC: From Small Cap to Life Sciences Market Disruptor!
- The Crash Has Already Started (Most Just Don’t See It Yet)
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
